QTRX 📈 Quanterix - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74766Q1013
QTRX: Protein Detection Platforms, Assays, Instruments, Reagents, Antibodies, Services
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts. Web URL: https://www.quanterix.com
Additional Sources for QTRX Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
QTRX Stock Overview
Market Cap in USD | 476m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 2017-12-07 |
QTRX Stock Ratings
Growth 5y | -68.4% |
Fundamental | -38.0% |
Dividend | - |
Rel. Strength Industry | -2843 |
Analysts | 4.2/5 |
Fair Price Momentum | 7.55 USD |
Fair Price DCF | - |
QTRX Dividends
No Dividends PaidQTRX Growth Ratios
Growth Correlation 3m | -42.6% |
Growth Correlation 12m | -89.7% |
Growth Correlation 5y | -60.5% |
CAGR 5y | -15.46% |
CAGR/Mean DD 5y | -0.27 |
Sharpe Ratio 12m | -1.25 |
Alpha | -101.60 |
Beta | 1.66 |
Volatility | 73.68% |
Current Volume | 547.6k |
Average Volume 20d | 375.4k |
What is the price of QTRX stocks?
As of December 21, 2024, the stock is trading at USD 10.50 with a total of 547,647 shares traded.
Over the past week, the price has changed by -10.48%, over one month by -9.67%, over three months by -35.51% and over the past year by -63.95%.
As of December 21, 2024, the stock is trading at USD 10.50 with a total of 547,647 shares traded.
Over the past week, the price has changed by -10.48%, over one month by -9.67%, over three months by -35.51% and over the past year by -63.95%.
Is Quanterix a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Quanterix (NASDAQ:QTRX) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -37.98 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of QTRX as of December 2024 is 7.55. This means that QTRX is currently overvalued and has a potential downside of -28.1%.
Probably not. Based on ValueRay Fundamental Analyses, Quanterix (NASDAQ:QTRX) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -37.98 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of QTRX as of December 2024 is 7.55. This means that QTRX is currently overvalued and has a potential downside of -28.1%.
Is QTRX a buy, sell or hold?
Quanterix has received a consensus analysts rating of 4.20. Therefor, it is recommend to buy QTRX.
Quanterix has received a consensus analysts rating of 4.20. Therefor, it is recommend to buy QTRX.
- Strong Buy: 2
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecast for QTRX stock price target?
According to ValueRays Forecast Model, QTRX Quanterix will be worth about 8.5 in December 2025. The stock is currently trading at 10.50. This means that the stock has a potential downside of -18.95%.
According to ValueRays Forecast Model, QTRX Quanterix will be worth about 8.5 in December 2025. The stock is currently trading at 10.50. This means that the stock has a potential downside of -18.95%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 19.9 | 89.8% |
Analysts Target Price | 30 | 185.7% |
ValueRay Target Price | 8.5 | -19% |